# Ph 1 Study of ADI-PEG 20 Plus Low Dose Cytarabine in Older Patients With AML

> **NCT02875093** · PHASE1 · TERMINATED · sponsor: **Polaris Group** · enrollment: 23 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** ADI-PEG 20
- **DRUG:** Cytarabine

## Key facts

- **NCT ID:** NCT02875093
- **Lead sponsor:** Polaris Group
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-01-20
- **Primary completion:** 2019-07-10
- **Final completion:** 2019-07-10
- **Target enrollment:** 23 (ACTUAL)
- **Why stopped:** Study Termination
- **Last updated:** 2020-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02875093

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02875093, "Ph 1 Study of ADI-PEG 20 Plus Low Dose Cytarabine in Older Patients With AML". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02875093. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*